The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: A systematic review

13Citations
Citations of this article
74Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The objective of this systematic review was to assess the published literature on the effectiveness of exenatide twice daily (exenatide) in clinical practice, specifically its effects on haemoglobin A1c (A1C), fasting glucose (FG), weight, systolic blood pressure (SBP), medication use, hospitalization and cardiovascular disease (CVD) outcomes. A systematic literature search using the MEDLINE database of English language literature published between January 2005 and May 2011 was performed. The review included retrospective or prospective observational studies that included 100 or more patients per treatment group. A total of 15 studies meeting the inclusion criteria were identified. The studies revealed significant reductions of -0.4 to -0.9% in A1C, -10 mg/dl in FG, -2 to -11 kg in body weight and -2 to -11 mmHg in SBP. Statistically significant reductions in the use or dosage of either oral glucose-lowering medications or insulin after initiating exenatide treatment were found in every observational study that assessed medication changes, including reductions in dosage of up to 75% in sulphonylureas dosages, 22% in metformin, 66% in thiazolidinediones (TZD) or TZD combination therapy and 75% in prandial insulin. Exenatide-treated patients experienced significantly lower rates of all-cause and CVD-related hospitalization and CVD events than patients treated with other therapies overall. In this review of observational studies, exenatide initiation was associated with significant reductions in clinically relevant outcomes. Improvements in A1C, FG, weight and SBP in the observational studies in this review were consistent with improvements observed in controlled clinical trials. © 2011 Blackwell Publishing Ltd.

References Powered by Scopus

Standards of medical care in diabetes-2011

0
2695Citations
N/AReaders
Get full text

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2

1394Citations
N/AReaders
Get full text

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

1353Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Neuroprotective and neurotrophic actions of glucagon-like peptide-1: An emerging opportunity to treat neurodegenerative and cerebrovascular disorders

212Citations
N/AReaders
Get full text

Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

86Citations
N/AReaders
Get full text

Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes

84Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Best, J. H., Lavillotti, K., Deyoung, M. B., & Garrison, L. P. (2012). The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: A systematic review. Diabetes, Obesity and Metabolism. Blackwell Publishing Ltd. https://doi.org/10.1111/j.1463-1326.2011.01533.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 22

54%

Researcher 12

29%

Professor / Associate Prof. 7

17%

Readers' Discipline

Tooltip

Medicine and Dentistry 32

67%

Pharmacology, Toxicology and Pharmaceut... 9

19%

Psychology 4

8%

Nursing and Health Professions 3

6%

Save time finding and organizing research with Mendeley

Sign up for free